CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including:

• Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer
• Results of the phase II REJOICE-Ovarian01 study in patients with platinum-resistant disease
• How R-DXd may be incorporated into the treatment paradigm
• Other investigational CDH6-targeting ADCs: CUSP06, SIM0505

Presenters:

Kathleen N. Moore, MD, MS, FASCO Deputy Director and Cancer Therapeutics Co-LeadStephenson Cancer Center at the University of OklahomaProfessorDepartment of OB/GynASCO BODOklahoma City, Oklahoma

Isabelle Ray-Coquard, MD, PhD President of the Gineco GroupCentre Leon BérardReshape Lab Inserm u1290Université Claude Bernard Lyon EstLyon, France

Content based on an online CME program supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Link to full program: https://bit.ly/43PXoeP

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.